KNTE Stock Price, Kinnate Biopharma Inc. Quote, Chart

Market Summary

USD2.65

Market Closed

KNTE Stock Price

View Fullscreen

KNTE RSI Chart

KNTE Valuation

Market Cap

125.1M

Price/Earnings (Trailing)

-1.11

Price/Free Cashflow

-1.25

KNTE Price/Earnings (Trailing)

KNTE Profitability

Return on Equity

-70.7%

Return on Assets

-64.89%

Free Cashflow Yield

-79.94%

KNTE Fundamentals

KNTE Earnings

Earnings (TTM)

-112.6M

Earnings Growth (Yr)

45.96%

Earnings Growth (Qtr)

44.5%

Breaking Down KNTE Revenue

Last 7 days

0.4%

Last 30 days

6.4%

Last 90 days

12.2%

Trailing 12 Months

-56.7%

How does KNTE drawdown profile look like?

KNTE Financial Health

Current Ratio

13.19

KNTE Investor Care

Shares Dilution (1Y)

1.41%

Diluted EPS (TTM)

-2.42

Tracking the Latest Insider Buys and Sells of Kinnate Biopharma Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	farzan nima	back to issuer	-	-	-2,186	chief executive officer
Apr 03, 2024	tananbaum james b.	back to issuer	-	-	-13,718,300	-
Apr 03, 2024	meltz mark a	back to issuer	-	-	-27,578	coo general counsel secretary
Apr 03, 2024	gordon carl l	back to issuer	-	-	-8,009,730	-
Apr 03, 2024	foresite capital management iv, llc	back to issuer	-	-	-13,718,300	-
Apr 03, 2024	orbimed advisors llc	back to issuer	-	-	-8,009,730	-
Apr 03, 2024	flaherty keith t.	back to issuer	-	-	-66,377	-
Apr 03, 2024	krishnamohan neha	back to issuer	-	-	-64,087	chief financial officer
Mar 01, 2024	meltz mark a	sold (taxes)	-1,445	2.59	-558	coo general counsel secretary
Mar 01, 2024	krishnamohan neha	sold (taxes)	-3,900	2.59	-1,506	chief financial officer

Which funds bought or sold KNTE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	BML Capital Management, LLC	added	6.54	217,286	1,326,940	0.89%
Apr 17, 2024	DELTEC ASSET MANAGEMENT LLC	new	-	2,765,870	2,765,870	0.54%
Apr 12, 2024	Vida Ventures Advisors, LLC	sold off	-100	-5,232,420	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	4.9	1,079,800	2,471,700	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	295	629,953	740,512	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	reduced	-9.43	279,000	803,000	0.07%
Feb 15, 2024	JANE STREET GROUP, LLC	added	215	148,797	183,118	-%
Feb 15, 2024	Exome Asset Management LLC	new	-	198,720	198,720	0.20%
Feb 15, 2024	BARCLAYS PLC	unchanged	-	14,000	35,000	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	added	187,755	1,335,230	1,335,650	-%

Are Funds Buying or Selling KNTE?

Are funds buying KNTE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KNTE

No. of Funds

Unveiling Kinnate Biopharma Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	foresite capital fund v, l.p.	0%	0	SC 13D/A
Feb 22, 2024	foresite capital fund v, l.p.	20.5%	9,671,643	SC 13D/A
Feb 21, 2024	orbimed advisors llc	16.1%	7,559,729	SC 13D/A
Feb 14, 2024	lynx1 capital management lp	4.2%	1,997,006	SC 13G/A
Feb 14, 2024	nextech v oncology s.c.s., sicav-sif	0.0%	0	SC 13G/A
Feb 14, 2024	tang capital partners lp	5.5%	2,601,647	SC 13G/A
Nov 27, 2023	tang capital partners lp	6.3%	2,965,715	SC 13G
Nov 17, 2023	foresite capital fund v, l.p.	20.5%	9,671,643	SC 13D/A
Nov 17, 2023	orbimed advisors llc	16.0%	7,559,729	SC 13D/A
Nov 14, 2023	foresite capital fund v, l.p.	20.5%	9,671,643	SC 13D/A

Recent SEC filings of Kinnate Biopharma Inc.

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	15-12G	15-12G
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	SC 13D/A	13D - Major Acquisition
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading

Peers (Alternatives to Kinnate Biopharma Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Kinnate Biopharma Inc. News

Latest updates

Kinnate Biopharma Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-9.0%	174	191	216	244	279	302	324	349	367	386	405	386	401
Current Assets	-7.1%	158	170	189	205	231	261	267	275	259	261	259	251	400
Cash Equivalents	10.3%	57.00	52.00	35.00	74.00	29.00	61.00	65.00	64.00	150	170	168	182	365
Net PPE	-8.0%	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	1.00	0.00	0.00	0.00	0.00
Liabilities	-21.9%	14.00	18.00	19.00	21.00	20.00	19.00	15.00	18.00	12.00	-	-	-	-
Current Liabilities	-24.0%	12.00	16.00	16.00	18.00	17.00	15.00	11.00	14.00	12.00	10.00	8.00	8.00	7.00
Shareholder's Equity	-7.6%	159	172	198	223	223	248	274	296	319	341	361	379	393
Retained Earnings	-4.8%	-372	-355	-324	-292	-259	-227	-197	-170	-143	-116	-92.23	-70.79	-53.33
Additional Paid-In Capital	0.7%	531	528	522	516	484	479	474	468	463	458	454	449	447
Shares Outstanding	0.0%	47.00	47.00	47.00	47.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	43.00	43.00
Float	-	-	-	76.00	-	-	-	367	-	-	-	634	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	32.0%	-17,365	-25,535	-29,423	-27,720	-23,748	-20,658	-23,541	-21,087	-22,523	-17,641	-17,459	-13,442	-13,776	-8,022	-5,709	-2,674
Share Based Compensation	-27.5%	3,830	5,281	5,403	5,404	4,942	4,981	4,882	4,777	4,302	4,161	3,760	2,793	1,226	714	410	128
Cashflow From Investing	-46.8%	22,700	42,633	-10,884	55,420	17,567	16,956	23,277	-64,630	2,338	18,763	-32,044	-169,631	-31,350	-226	-104	-29.00
Cashflow From Financing	-100.0%	-	57.00	1,251	-9,116	193	190	652	125	557	193	35,487	-	253,729	97,165	18.00	-13.00

KNTE Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 90,767	$ 88,150
General and administrative	28,241	30,371
Restructuring costs	2,168	0
Total operating expenses	121,176	118,521
Loss from operations	(121,176)	(118,521)
Other income, net	8,527	2,250
Net loss	$ (112,649)	$ (116,271)
Weighted-average shares outstanding, basic (in shares)	46,575,378	44,065,749
Weighted-average shares outstanding, diluted (in shares)	46,575,378	44,065,749
Net loss per share, basic (in dollars per share)	$ (2.42)	$ (2.64)
Net loss per share, diluted (in dollars per share)	$ (2.42)	$ (2.64)
Comprehensive loss:
Net loss	$ (112,649)	$ (116,271)
Other comprehensive loss:
Currency translation adjustments	(6)	1
Unrealized gain (loss) on investments	1,404	(887)
Total comprehensive loss	$ (111,251)	$ (117,157)

KNTE Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 56,998	$ 29,261
Cash at consolidated joint venture	0	25,725
Short-term investments	97,036	172,214
Prepaid expenses and other current assets	4,143	3,637
Total current assets	158,177	230,837
Property and equipment, net	2,272	3,071
Right-of-use lease assets	2,488	3,377
Long-term investments	10,259	39,139
Restricted cash	371	371
Other non-current assets	38	2,031
Total assets	173,605	278,826
Current liabilities:
Accounts payable	2,031	2,970
Accrued expenses	9,072	13,206
Current portion of operating lease liabilities	892	991
Total current liabilities	11,995	17,167
Operating lease liabilities, long-term	2,283	3,191
Total liabilities	14,278	20,358
Commitments and contingencies (See Note 13)
Redeemable convertible noncontrolling interests	0	35,000
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized at December 31,2023 and 2022; 0 shares outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value; 1,000,000,000 shares authorized at December 31, 2023 and 2022; 47,124,349 and 44,342,292 shares issued and outstanding at December 31, 2023 and 2022 , respectively	5	4
Additional paid-in capital	531,346	484,237
Accumulated other comprehensive loss	(12)	(1,410)
Accumulated deficit	(372,012)	(259,363)
Total stockholders' equity	159,327	223,468
Total liabilities, redeemable convertible noncontrolling interests and stockholders' equity	$ 173,605	$ 278,826

About Kinnate Biopharma Inc.

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

CEO	Mr. Nima Farzan M.B.A.
WEBSITE	kinnate.com
INDUSTRY	Biotechnology
EMPLOYEES	84

Kinnate Biopharma Inc. Frequently Asked Questions

What is the ticker symbol for Kinnate Biopharma Inc.? What does KNTE stand for in stocks?

KNTE is the stock ticker symbol of Kinnate Biopharma Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kinnate Biopharma Inc. (KNTE)?

As of Wed Apr 03 2024, market cap of Kinnate Biopharma Inc. is 125.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KNTE stock?

You can check KNTE's fair value in chart for subscribers.

What is the fair value of KNTE stock?

You can check KNTE's fair value in chart for subscribers. The fair value of Kinnate Biopharma Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kinnate Biopharma Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KNTE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kinnate Biopharma Inc. a good stock to buy?

The fair value guage provides a quick view whether KNTE is over valued or under valued. Whether Kinnate Biopharma Inc. is cheap or expensive depends on the assumptions which impact Kinnate Biopharma Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KNTE.